RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Sumitomo Pharma Co Stock

Sumitomo Pharma Co Equity 2024

Sumitomo Pharma Co Equity

156.06 B JPY

Ticker

4506.T

ISIN

JP3495000006

WKN

858257

In 2024, Sumitomo Pharma Co's equity was 156.06 B JPY, a -74.33% increase from the 607.89 B JPY equity in the previous year.

Sumitomo Pharma Co Aktienanalyse

What does Sumitomo Pharma Co do?

Sumitomo Dainippon Pharma Co Ltd is a biopharmaceutical company headquartered in Osaka, Japan. It was originally founded as Dainippon Pharmaceutical Co. Ltd in 1885 and later merged with Sumitomo Pharmaceuticals in 2005 to form the new Sumitomo Dainippon Pharma. The company operates in various areas, such as psychiatric and neurological medicine, oncology, dermatology, and infectious diseases. The products include both prescription and over-the-counter medications. In psychiatric and neurological medicine, Sumitomo Dainippon Pharma offers drugs that can be used to treat depression, anxiety disorders, schizophrenia, and bipolar disorders. One of the most well-known medications in this category is the antipsychotic Latuda, which is used for schizophrenia and bipolar disorder. In oncology, Sumitomo Dainippon Pharma has developed medications that can be used in the treatment of cancers such as lung, liver, pancreatic, colorectal, and blood cancer. The company is also involved in developing treatments for rare forms of cancer and immune-mediated diseases. In dermatology, Sumitomo Dainippon Pharma has developed medications for the treatment of skin and nail infections, psoriasis, and atopic dermatitis. The company is also working on innovative treatment approaches for skin cancer and other types of skin diseases. Sumitomo Dainippon Pharma is also involved in the development of treatments for infectious diseases, including medications for HIV and hepatitis C. The business model of Sumitomo Dainippon Pharma is based on the development of new drugs and the marketing of prescription and over-the-counter medications on a global level. The company focuses on researching and developing drugs that can address significant medical needs and that differentiate themselves from other medications on the market. The products are registered and marketed in various countries, especially in the US and Japan. Sumitomo Dainippon Pharma invests significantly in research and development. The company has R&D sites in Japan, the US, UK, and Ireland. It also collaborates with other companies to leverage innovative technologies and accelerate the development of new medications. Overall, Sumitomo Dainippon Pharma has a long history in the pharmaceutical industry and is committed to creating a wide range of medications and therapies for various diseases and conditions. The company is dedicated to improving the lives of patients and contributing to the well-being of society as a whole. Sumitomo Pharma Co ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Equity Details

Analyzing Sumitomo Pharma Co's Equity

Sumitomo Pharma Co's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Sumitomo Pharma Co's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Sumitomo Pharma Co's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Sumitomo Pharma Co's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Sumitomo Pharma Co’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Sumitomo Pharma Co stock

What is the equity of Sumitomo Pharma Co this year?

Sumitomo Pharma Co has equity of 156.06 B JPY this year.

What was the equity of Sumitomo Pharma Co compared to the previous year?

The equity of Sumitomo Pharma Co has increased/decreased by -74.33% decreased compared to the previous year.

What impact does a high equity have on investors of Sumitomo Pharma Co?

A high equity is advantageous for investors of Sumitomo Pharma Co as it is an indicator of the company's financial stability and its ability to manage risks and challenges.

What impact does low equity have on investors of Sumitomo Pharma Co?

A low equity can be a risk for investors of Sumitomo Pharma Co, as it can put the company in a weaker financial position and impair its ability to manage risks and challenges.

How does an increase in equity of Sumitomo Pharma Co affect the company?

An increase in equity of Sumitomo Pharma Co can strengthen the company's financial position and improve its ability to make investments in the future.

How does a reduction in the equity of Sumitomo Pharma Co affect the company?

A reduction in equity of Sumitomo Pharma Co can affect the financial situation of the company and lead to a higher dependence on debt capital.

What are some factors that influence the equity of Sumitomo Pharma Co?

Some factors that can affect the equity of Sumitomo Pharma Co include profits, dividend payments, capital increases, and acquisitions.

Why is the equity of Sumitomo Pharma Co so important for investors?

The equity of Sumitomo Pharma Co is important for investors as it is an indicator of the financial strength of the company and can be an indication of how well the company is able to fulfill its financial obligations.

What strategic measures can Sumitomo Pharma Co take to change the equity?

To change equity, Sumitomo Pharma Co can take various measures such as increasing profits, conducting capital increases, reducing expenses, and acquiring companies. It is important for the company to perform a thorough review of its financial situation to determine the best strategic actions to modify its equity.

How much dividend does Sumitomo Pharma Co pay?

Over the past 12 months, Sumitomo Pharma Co paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Sumitomo Pharma Co is expected to pay a dividend of -5.34 JPY.

What is the dividend yield of Sumitomo Pharma Co?

The current dividend yield of Sumitomo Pharma Co is .

When does Sumitomo Pharma Co pay dividends?

Sumitomo Pharma Co pays a quarterly dividend. This is distributed in the months of October, April, October, April.

How secure is the dividend of Sumitomo Pharma Co?

Sumitomo Pharma Co paid dividends every year for the past 2 years.

What is the dividend of Sumitomo Pharma Co?

For the upcoming 12 months, dividends amounting to -5.34 JPY are expected. This corresponds to a dividend yield of -0.95 %.

In which sector is Sumitomo Pharma Co located?

Sumitomo Pharma Co is assigned to the 'Health' sector.

Wann musste ich die Aktien von Sumitomo Pharma Co kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Sumitomo Pharma Co from 6/1/2023 amounting to 7 JPY, you needed to have the stock in your portfolio before the ex-date on 3/30/2023.

When did Sumitomo Pharma Co pay the last dividend?

The last dividend was paid out on 6/1/2023.

What was the dividend of Sumitomo Pharma Co in the year 2023?

In the year 2023, Sumitomo Pharma Co distributed 28 JPY as dividends.

In which currency does Sumitomo Pharma Co pay out the dividend?

The dividends of Sumitomo Pharma Co are distributed in JPY.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Sumitomo Pharma Co

Our stock analysis for Sumitomo Pharma Co Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Sumitomo Pharma Co Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.